iRadimed (FRA:46K) Total Long-Term Assets: €24.19 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:46K iRadimed Corp FRA:46K
91 GF Score
Price €82.00
GF Value €56.55
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is iRadimed Total Long-Term Assets?

iRadimed FRA:46K +0.61% 91 Total Long-Term Assets is €24.19 Mil as of Mar. 2026. GuruFocus rates FRA:46K with a GF Score™ of 91/100 and a GF Value™ of €56.55 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. iRadimed's Total Long-Term Assets for the quarter that ended in Mar. 2026 was €24.19 Mil.

iRadimed Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for iRadimed's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

iRadimed Total Long-Term Assets Chart

iRadimed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.87 7.57 14.81 22.05 23.55

iRadimed Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.21 25.39 23.55 24.19 24.52
FRA:46K
91GF Score
iRadimed Corp FRA:46K
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

iRadimed Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €24.19 Mil mean?
iRadimed (FRA:46K) has a Total Long-Term Assets of €24.19 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on iRadimed and its competitors.
Is iRadimed's Total Long-Term Assets too high?
iRadimed's current Total Long-Term Assets is €24.19 Mil. Overall, iRadimed has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iRadimed's Total Long-Term Assets compare to AORT and TNDM?
iRadimed's Total Long-Term Assets of €24.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Medical Devices & Instruments company?
A good Total Long-Term Assets depends on the Medical Devices & Instruments industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on iRadimed and its competitors. iRadimed's current Total Long-Term Assets is €24.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iRadimed stock overvalued right now?
Based on GuruFocus' analysis, iRadimed (FRA:46K) is currently considered Significantly Overvalued. The stock's GF Value™ is €56.55, compared to a current price of €82.00 — trading 45% above its estimated fair value. The current Total Long-Term Assets is €24.19 Mil. iRadimed's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For iRadimed (FRA:46K), the current Total Long-Term Assets is €24.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is iRadimed (FRA:46K) Overvalued in 2026?

Based on GuruFocus' analysis, iRadimed stock appears to be overvalued. The current stock price of €82.00 is trading 45% above its estimated GF Value™ of €56.55. GuruFocus considers iRadimed to be Significantly Overvalued.

Key valuation signals for FRA:46K:

  • Total Long-Term Assets: €24.19 Mil
  • GF Value™: €56.55 vs. price of €82.00 (45% above fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the FRA:46K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

iRadimed Business Description

Other Exchanges IRMD:USA
Address 12705 Ingenuity Drive, Orlando, FL, USA, 32826
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
91GF Score

Get the complete analysis for FRA:46K

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€82.00
Price
€56.55
GF Value